Qiagen Stock Price, News & Analysis

QIAGEN has expanded its digital PCR portfolio with new solutions for lentivirus-based cell and gene therapies. The company introduced key products including the QIAcuity RCL Quant Kit for safety testing, new CGT dPCR assays for viral measurements, and a specialized Lentivirus Lysis Kit for improved workflow.

The expansion specifically targets quality control in the manufacturing of advanced treatments like CAR-T cell therapy, a personalized cancer immunotherapy. The new offerings provide:

• Enhanced detection of replication-competent lentivirus
• Eight different wet-lab verified lentiviral targets
• Improved accuracy in viral titer measurement
• Streamlined protocols for vector copy number determination

This portfolio enhancement strengthens QIAGEN's position as a quality control partner for biotech companies, CDMOs, and therapy developers. The solutions complement existing products for residual DNA quantification, mycoplasma testing, and viral vector analysis, supporting the growing cell and gene therapy industry's regulatory compliance needs.

QIAGEN (NYSE: QGEN) has announced significant updates to its cancer genomic profiling portfolio at the AACR Annual Meeting 2025. The company unveiled new QIAseq panels for comprehensive genomic profiling, capable of analyzing over 700 genes for research and clinical applications.

Key developments include:

• Expansion of QIAseq xHYB CGP portfolio with DNA and RNA panels
• Launch of QIAcuity RCL Quant Kit and CGT dPCR assays for cell and gene therapy quality control
• Partnership with Element Biosciences to integrate QIAseq xHYB CGP Panels into their Trinity workflow
• Collaboration with Myriad Genetics to develop a new sequencing-based HRD assay planned for 2025 launch
• Introduction of HSMD Research, a free, version of the Human Somatic Mutation Database covering 25 key genes in cancer research

QIAGEN (NYSE: QGEN) has announced plans to launch three new sample preparation instruments between 2025 and 2026. The flagship QIAsymphony Connect, scheduled for phased launch in 2025, will feature enhanced capabilities for oncology and genomics workflows, processing up to 96 samples simultaneously with improved automation and digital connectivity.

The QIAsprint Connect, launching in 2026, will be QIAGEN's first high-throughput system, capable of processing 192 samples per run with less than 30 minutes hands-on time, scaling up to 600 samples daily. The system reduces plastic waste by 50% and supports various sample types including plant, microbial, soil, and human tissues.

The QIAmini, also set for 2026 launch, targets the low-throughput segment, offering smaller labs an entry point into automation. These launches complement QIAGEN's existing automation portfolio, including the QIAcube Connect and EZ2 Connect systems.

QIAGEN N.V. (NYSE: QGEN) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will release its Q1 2025 results on Wednesday, May 7, 2025, after market close at 22:05 Frankfurt time. A conference call is scheduled for Thursday, May 8, at 15:00 Frankfurt time, with dial-in options available for US, UK, and German investors. The company will provide a webcast option and call-back service for participants, with replay access available after the event.

QIAGEN (NYSE: QGEN) reported strong preliminary Q1 2025 results, with net sales growing 7% at constant exchange rates (CER) to approximately $483 million, exceeding the previous outlook of 3% CER growth. Adjusted diluted EPS is expected to be at least $0.55 CER, surpassing the earlier guidance of $0.50 CER.

Key growth drivers include:

• QuantiFERON latent TB test: ~15% CER growth
• QIAstat-Dx syndromic testing system: >35% CER growth
• QIAcuity digital PCR system and QIAGEN Digital Insights: high-single-digit CER gains

Based on strong Q1 performance, QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to approximately $2.35 CER (up from $2.28 CER). The company expects to achieve its mid-term adjusted operating income margin target of 31% ahead of the original 2028 timeline.

QIAGEN (NYSE:QGEN) reports strong preliminary Q1 2025 results, exceeding previous guidance. Net sales grew approximately 5% (+7% at constant exchange rates) to about $483 million, surpassing the outlook of 3% CER growth.

The company's QuantiFERON latent TB test saw ~15% CER growth, while the QIAstat-Dx syndromic testing system advanced above 35% CER. The QIAcuity digital PCR system and QIAGEN Digital Insights both achieved high-single-digit CER gains. Sample technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.

QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from $2.28 CER, while maintaining its goal to improve adjusted operating income margin to above 30%. Q1 2025 adjusted diluted EPS is expected to be at least $0.55 CER, exceeding the previous outlook of $0.50 CER.

QIAGEN (NYSE: QGEN) has launched the QIAprep& Plasmodium Kit and two companion assays to enhance malaria research and surveillance. The new solution combines sample preparation and quantitative PCR into a single workflow for detecting malaria-causing parasites from blood samples.

The kit enables detection of all five Plasmodium species with high sensitivity (one parasite per microliter) and is compatible with both liquid and dried blood samples. The technology includes two key assays: the QIAGEN Pf/Non-Pf Detection Assay for screening Plasmodium falciparum, and the QIAGEN Pv/Pm/Po/Pk Detection Assay for distinguishing between P. vivax, P. malariae, P. ovale, and P. knowlesi.

This launch addresses a critical global health challenge, as malaria caused over 250 million cases worldwide in 2024, with more than 90% occurring in Africa. The solution aims to support mixed-infection tracking, vaccine impact assessment, and malaria control strategies, particularly in regions with healthcare infrastructure.

QIAGEN (NYSE: QGEN) has announced the filing of its annual report on Form 20-F with the U.S. Securities and Exchange Commission, which includes audited consolidated financial statements for the fiscal year ended December 31, 2024. The report is accessible on QIAGEN's website, and the company will provide printed copies free of charge to shareholders upon request through their contact form or via email at ir@qiagen.com.

QIAGEN (NYSE: QGEN) has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its U.S. syndromic testing portfolio. This panel enables rapid detection of five common bacterial pathogens in outpatient settings, including Campylobacter, Salmonella, STEC, Shigella, and Yersinia enterocolitica.

This marks QIAGEN's second FDA clearance in 2025 and sixth regulatory clearance for QIAstat-Dx panels in the past 10 months. The new panel complements the existing QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers both bacterial and viral targets.

The system delivers results in about one hour with minimal hands-on time, using real-time PCR technology. QIAGEN's QIAstat-Dx platform has achieved significant market penetration with over 4,600 instruments placed worldwide through 2024. The company is awaiting U.S. regulatory clearance for its new QIAstat-Dx Rise instrument, capable of processing up to 160 tests daily.